Therapeutics News and Research

RSS

Comprehensive gene map of malaria parasite offers path to better treatments

A new, comprehensive map of all the genes essential for blood infections in Plasmodium knowlesi (P. knowlesi), a parasite that causes malaria in humans, has been generated by researchers at Harvard T.H. Chan School of Public Health and colleagues.

7 Feb 2025

Early immune system changes contribute to lung damage in cystic fibrosis

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the disease causes changes in the immune system early in life, presumably even in newborns.

7 Feb 2025

Researchers uncover brain mechanisms that help overcome instinctive fears

Researchers at the Sainsbury Wellcome Centre (SWC) at UCL have unveiled the precise brain mechanisms that enable animals to overcome instinctive fears.

6 Feb 2025

New study identifies potential drug targets for heart failure

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart failure is classified into two major clinical subtypes- heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).

6 Feb 2025

Granzyme K identified as key trigger of complement system in autoimmune diseases

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that patrols our body, ever vigilant for signs of infection or injury

6 Feb 2025

RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancer

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report."

6 Feb 2025

MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market leader of on-target and off-target editing assessment services for cell and gene therapies.

From MaxCyte, Inc. 6 Feb 2025

Communication between body muscle and pituitary gland may play unexpected role in female fertility

A newly discovered line of communication between body muscle and the pituitary gland may play an unexpected role in female fertility, according to a new study.

6 Feb 2025

New nasal vaccine for COVID-19 set to begin clinical trial in the U.S.

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug application from Ocugen, Inc. was approved by the Food and Drug Administration (FDA). Ocugen, a U.S.-based biotechnology company, licensed the innovative technology from WashU in 2022.

5 Feb 2025

Study reveals how healthy stem cells transform into cancer cells

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise.

5 Feb 2025

Engineered fat cells starve tumors and prevent cancer growth

Scientists transformed energy-storing white fat cells into calorie-burning 'beige' fat. Once implanted, they outcompeted tumors for resources, beating back five different types of cancer in lab experiments.

4 Feb 2025

Blocking a protein could halt the growth of fast-growing cancers

Preventing the cell's protein factories from making the notorious cancer-causing protein MYC could stop out-of-control tumors.

4 Feb 2025

New microscopy technique offers affordable way to study cancer cell metabolism

Understanding how tumors change their metabolism to resist treatments is a growing focus in cancer research.

3 Feb 2025

New targeted therapy could bring relief to people with lichen planus

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a chronic inflammatory skin condition of the skin, hair, nails, mouth and genitals.

3 Feb 2025

New compound shows promise for treating psoriasis with blue light activation

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques).

3 Feb 2025

Researchers develop model to identify tumor-fighting immune cells in lung cancer patients

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

3 Feb 2025